login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

US researchers identify “master coordinator” for aortic dissection


Tuesday, 25 Jun 2013 12:07
Allan Brasier
Allan Brasier

New findings from a study carried out by investigators from the University of Texas Medical Branch (UTMB) at Galveston, USA, have identified a lymphocyte that is responsible for the cellular inflammation of the aortic wall that causes aortic dissections.

In earlier studies, researchers from the UTMB at Galveston linked the blood-pressure-regulating molecule, angiotensin II, to the immune signalling protein IL6, which they determined played a major role in producing aortic dissections. Exactly how IL6 generated the inflammation leading to aortic dissection remained unknown, however.

Now the UTMB researchers have found what they believe is the missing piece of the puzzle in a group of cells called Th17 lymphocytes. Part of the body’s adaptive immune system, these cells normally serve a protective function; they generate a protein called IL17 to bring other cells to support immune defences. But in laboratory mouse experiments, the scientists found that locally produced vascular IL6 promotes Th17 formation and accumulation in the vessel wall. There, Th17 lymphocytes instigate a misguided immune attack on the aorta.

“In our study, we compared the effects of angiotensin II on normal mice and mice deficient in Th17 cells, either genetically or by blocking its action,” said UTMB professor Allan Brasier, senior author of a paper on the discovery now online in the journal Arteriosclerosis, Thrombosis, and Vascular Biology. “The results showed us that interfering with the Th17 lymphocyte significantly reduces dissections. These data suggest that Th17 lymphocyte is the master coordinator of cellular inflammation in the vessel wall.”

To establish the clinical relevance of their findings, the scientists examined tissue samples from patients with a genetic mutation that predisposed them to aortic dissections. The samples, which were derived from a bank maintained by University of Texas Health Science Center at Houston professor and paper author Dianna Milewicz, showed clear signs of Th17 cell accumulation.

“The idea here is that the immune system has evolved to protect us against viruses and bacteria, these sorts of things,” Brasier said. “But under certain pathological conditions, the immune system can actually produce disease through chronic inflammation.”

Other authors of the paper include graduate students Xiaoxi Ju and Talha Ijaz, research associates Hong Sun, Chang Lee and Wanda Lejeune, assistant professors Sutapa Ray and Adrian Recinos and professor Ronald Tilton, as well as UTHSC-Houston’s Dong-Chuan Guo.




Add New Comment

Most popular


Incraft low-profile endograft launched in Europe and Canada
Wednesday, 10 Sep 2014
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from ... Incraft low-profile endograft launched in Europe and Canada

First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

Features


Not all drug-eluting balloons are equal
Wednesday, 15 Oct 2014
Thomas Zeller, Bad Krozingen, Germany, analyses the results of two recent randomised controlled trials comparing drug-eluting balloons to angioplasty alone in femoropopliteal lesions. Not all drug-eluting balloons are equal

Renal stenting may benefit patients excluded from randomised trials, says expert consensus
Wednesday, 15 Oct 2014
Sahil A Parikh, Case Western Reserve University School of Medicine, Cleveland, USA, speaks to Vascular News about the Society for Cardiovascular Angiography and Interventions expert consensus on ... Renal stenting may benefit patients excluded from randomised trials, says expert consensus

Profiles


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions